About: Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro
Creator	Zhang, Jun Yang, Yang Ma, Jian Yuan, Quan Ge, Sheng-Xiang Xia, Ning-Shao Cao, Jia-Li Qiao, Xiao-Yang Shen, Chen-Guang Shi, Tian-Shu Xiong, Hua-Long Zhang, Tian-Ying
Source	BioRxiv
abstract	To identify drugs that are potentially used for the treatment of COVID-19, the potency of 1403 FDA-approved drugs were evaluated using a robust pseudovirus assay and the candidates were further confirmed by authentic SARS-CoV-2 assay. Four compounds, Clomiphene (citrate), Vortioxetine, Vortioxetine (hydrobromide) and Asenapine (hydrochloride), showed potent inhibitory effects in both pseudovirus and authentic virus assay. The combination of Clomiphene (citrate), Vortioxetine and Asenapine (hydrochloride) is much more potent than used alone, with IC50 of 0.34 μM.
has issue date	2020-06-05(xsd:dateTime)
bibo:doi	10.1101/2020.06.05.135996
has license	biorxiv
sha1sum (hex)	fb921a8d4534a3693e061acc58444e75fa04275d
schema:url	https://doi.org/10.1101/2020.06.05.135996
resource representing a document's title	Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro
schema:publication	bioRxiv
resource representing a document's body	covid:fb921a8d4534a3693e061acc58444e75fa04275d#body_text
is schema:about of	named entity 'Vortioxetine' named entity 'Clomiphene' named entity 'SARS-CoV-2' named entity 'FDA' named entity 'COVID-19' named entity 'The combination' named entity 'potent' named entity 'infection' named entity 'pseudovirus' named entity 'SARS-CoV-2 virus' named entity 'Amiodarone' named entity 'combination therapy' named entity 'non-linear regression' named entity 'VSV' named entity 'genome' named entity 'IC50' named entity 'pseudovirus' named entity 'citrate' named entity 'Asenapine' named entity 'half maximal inhibitory concentration' named entity 'SARS-CoV-2' named entity 'Vortioxetine' named entity 'Vortioxetine' named entity 'COVID-19' named entity 'Clomiphene' named entity 'Vortioxetine' named entity 'hydrochloride' named entity 'assay' named entity 'virus' named entity 'IC50' named entity 'hydrochloride' named entity 'citrate' named entity 'FDA' named entity 'potency' named entity 'FDA' named entity 'SARS-CoV-2' named entity 'pseudovirus' named entity 'Chloroquine' named entity 'Clomifene' named entity 'pharmacological' named entity 'virus' named entity 'COVID' named entity 'fluorescence' named entity 'infection' named entity 'schizophrenia' named entity 'bipolar I disorder' named entity 'SARS-CoV-2' named entity 'agonist' named entity 'VSV' named entity 'citrate' named entity 'combination therapies' named entity 'clinical evaluation' named entity 'infection' named entity 'virus infection' named entity 'SARS-CoV-2' named entity 'infection' named entity 'spike protein' named entity 'prophylaxis' named entity 'Chloroquine' named entity 'virus' named entity 'cytopathic effect' named entity 'citrate' named entity 'SARS-CoV-2' named entity 'virus' named entity 'antiviral drug' named entity 'SARS-CoV-2' named entity 'Vortioxetine' named entity 'pseudovirus' named entity 'cytotoxicity' named entity 'vesicular stomatitis virus' named entity 'chloride' named entity 'virtual screening' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software